Agenda

Schedule
8:30am- 8:40am Opening Remarks

Dr. Susan Furth, MD, PhD
Chief Scientific Officer & Executive Vice President 

8:40am- 9:10am Morning KeynoteHistory of Vaccine Development in Philadelphia”

Stanley A. Plotkin, MD

Professor Emeritus, Department of Pediatrics, Penn Perelman School of Medicine
9:10am-10:10am Session 1: Vaccines in Model Systems
9:10am-9:30am “Immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection” Daniel Kulp, PhDAssociate Professor, Vaccine & Immunotherapy Center, The Wistar Institute
9:30am-9:50am “Sequential immunization strategies to elicit broadly neutralizing antibodies against HIV” Amelia Escolano, PhDAssistant Professor, Vaccine & Immunotherapy Center, The Wistar Institute
9:50am-10:10am “Nucleoside-modified mRNA vaccine to prevent genital herpes” Harvey Friedman, MDProfessor of Medicine, Penn Perelman School of Medicine

10:10am-10:30am

Break

10:30am-11:50am

Session 2: Determinants of Vaccine-induced Immunity
10:30am-10:50am “Development of a multivalent mRNA influenza vaccine to replace original antigenic sin with initial blessings of induced immunity” Scott Hensley, PhDProfessor of Microbiology, Penn Perelman School of Medicine
10:50am-11:10am

“Immune Health and immunity to SARS-CoV-2 vaccines”

John Wherry, PhDRichard and Barbara Schiffrin President’s Distinguished Professor; Chair, Department of Systems Pharmacology and Translational Therapeutics, Penn Perelman School of Medicine
11:10am-11:30am “Vaccine Readiness after Immune Reconstitution” Laura Vella, MD, PhDAssistant Professor of Pediatrics, Children’s Hospital of Philadelphia
11:30am-11:50am “Immune responses to SARS-CoV-2 mRNA vaccines in human lymph nodes” Michela Locci, PhDAssistant Professor of Microbiology, Penn Perelman School of Medicine

11:50am-12:30pm

Lunch

12:30pm-1:00pm

Afternoon Keynote: “Nucleoside Modified mRNA-LNP Therapeutics”

Drew Weissman, MD, PhDRoberts Family Professor in Vaccine Research; Director, Penn Institute for RNA Innovation, Penn Perelman School of Medicine 

1:00pm-2:00pm

Session 3: Vaccine Design, Adjuvants, and Delivery Systems
1:00pm-1:20pm "Invivo Genetic Delivery for tailoring immunization and immuno-biologics" David B. Weiner, PhDDirector, Vaccine & Immunotherapy Center; W.W. Smith Charitable Trust Professor in Cancer Research, Immunology, Microenvironment & Metastasis Program, The Wistar Institute
1:20pm-1:40pm “An MHC-independent synthetic vaccine-Boosting CAR T cell therapy and endogenous anti-tumor immunity in tandem” Leyuan Ma, PhDAssistant Professor of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia
1:40pm-2:00pm “Lipid nanoparticles are broadly applicable T follicular helper cell and humoral immune response adjuvants” Norbert Pardi, PhDAssistant Professor of Microbiology, Penn Perelman School of Medicine

2:00pm-3:00pm

Session 4: Clinical Trials in Vaccination
2:00pm-2:20pm

“COVID-19 Vaccines for Children”

Jeffrey Gerber, MD, PhD, MSCEWerner and Gertrude Henle Endowed Chair, Department of Pediatrics, Children’s Hospital of Philadelphia
2:20pm-2:40pm "Covid vaccine in adults, new strains and correlates of protection" Pablo Tebas, MDProfessor of Medicine, Penn Perelman School of Medicine
2:40pm-3:00pm

“Targeting Tumor Neoantigens”

Beatriz Carreno, PhDResearch Associate Professor in Pathology and Laboratory Medicine, Penn Perelman School of Medicine

3:00pm-3:20pm

Break

3:20pm-4:10pm

Session 5: Vaccine Policy
3:20pm-3:45pm “Minimizing the viral spread of bogus tales of vaccination side effects” Kathleen Hall Jamieson, PhD- Elizabeth Ware Packard Professor of Communication; Director, Annenberg Public Policy Center
3:45pm-4:10pm "Approving COVID-19 Vaccines for Children: When Do We Know Enough?" Paul Offit, PhD- Maurice R. Hilleman Chair of Vaccinology

4:10pm-4:40pm

Roundtable: What Makes a Leading Vaccine Center

ModeratorsLaura Vella, MD, PhD & Norbert Pardi, PhD

Jeffrey Gerber, MD, PhD
Amelia Escolano, PhD
David B. Weiner, PhD
Drew Weissman, MD, PhD

Scott Hensley, PhD

4:40pm-5:00pm

Closing Remarks

Dr. Jonathan Epstein, MD
Chief Scientific Officer & Executive Vice President 

5:00pm-6:00pm

Reception